
Sign up to save your podcasts
Or


In this episode, we explore groundbreaking Swedish research on GLP-1 receptor agonists as a potential new treatment for alcohol use disorder. Could diabetes medications like semaglutide revolutionize addiction treatment where traditional therapies have fallen short?
Faculty: David Gorelick, M.D. Host: Richard Seeber, M.D.
By Psychopharmacology Institute4.6
270270 ratings
In this episode, we explore groundbreaking Swedish research on GLP-1 receptor agonists as a potential new treatment for alcohol use disorder. Could diabetes medications like semaglutide revolutionize addiction treatment where traditional therapies have fallen short?
Faculty: David Gorelick, M.D. Host: Richard Seeber, M.D.

74 Listeners

142 Listeners

3,362 Listeners

160 Listeners

1,148 Listeners

1,351 Listeners

732 Listeners

168 Listeners

578 Listeners

472 Listeners

735 Listeners

12 Listeners

189 Listeners

150 Listeners

59 Listeners